Figure 4
From: Biomarkers of persistent renal vulnerability after acute kidney injury recovery
Susceptibility to AKI: plasma creatinine (pCr) (a–c), proteinuria (d–f) and creatinine clearance (ClCr) (g–i). B basal, CDDP cisplatin treatment (5 mg kg−1 body weight) group, CT control group, D4 day of maximum kidney damage after cisplatin treatment, G gentamicin administration, R0 day of recovery, R0 + G6 6 days of gentamicin treatment (50 mg kg−1 body weight) after R0, R1 1 week after recovery, R1 + G6 6 days of gentamicin treatment (50 mg kg−1 body weight) after R1, R2 2 weeks after recovery, R2 + G6 6 days of gentamicin treatment (50 mg kg−1 body weight) after R2. P < 0.01: * versus B.
